Brought to you by 
Intarcia files for IPO; withdrawn
20 Mar 2007
Executive Summary
Citing poor market conditions, Intarcia Therapeutics (acquires and develops drugs for cancer and infectious diseases) has withdrawn its intial public offering in which it planned to sell 5mm shares priced between $12 and $14 each.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Withdrawn
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Intarcia files for IPO; withdrawn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice